

*This document was used during the September 21, 2013, Assessment of Options Advisory panel meeting to facilitate the discussion of the research gaps in bipolar disorder.*

## Bipolar Disorder and Antipsychotic Use in Adolescents and Young Adults

<b><i>Research Areas</i></b>	<b><i>Notes</i></b>
<b><i>Population</i></b>	
3. How do the comparative safety and effectiveness of antipsychotic treatment in adolescents/young adults with bipolar disorder differ depending on <b>demographic differences</b> such as age group (e.g., under 18 versus 18-25), rural versus urban, race/ethnicity, and sex?	
4. How do the comparative safety and effectiveness of antipsychotic treatment in adolescents/young adults with bipolar disorder differ depending on <b>socioeconomic factors</b> such as income, insurance status, access to healthcare and to types of services, and level of caregiver/social support?	

<b><i>Intervention and Comparator</i></b>	
11. What are the comparative safety and effectiveness of <b>monotherapy compared to combination therapy</b> with antipsychotic drugs in adolescents/young adults with bipolar disorder?	
12. What are the comparative safety and effectiveness of <b>concurrent psychiatric medications</b> (e.g., antidepressants, anxiolytics, stimulants) given as adjuncts to antipsychotic drugs in adolescents/young adults with bipolar disorder?	
13. What are the comparative safety and effectiveness of <b>'mood stabilizing' medication classes</b> (e.g., lithium or antiepileptic drugs like lamotrigine or valproic acid) compared with antipsychotic drugs in adolescents/young adults with bipolar disorder?	

<p>14. What are the comparative safety and effectiveness of <b>antipsychotic drugs alone compared with the combination of antipsychotic drugs plus other nonpharmacologic interventions</b> (e.g., psychotherapy/counseling, peer and family support, supported employment, diet and physical activity interventions, assertive community treatment) in adolescents/young adults with bipolar disorder?</p>	
<p><b><i>Outcome</i></b></p>	
<p>15. What are the <b>key patient-centered and family-centered outcomes</b> for adolescents/young adults with bipolar disorder and their families, and how are these outcomes affected by different antipsychotic classes/agents?</p>	
<p>16. What are the comparative effects of antipsychotics on <b>core disease features</b> in adolescents/young adults with bipolar disorder, both in the immediate and long term?</p>	

<p>19. What are the comparative effects of antipsychotics on <b>social, academic, and occupational functioning</b> in adolescents/young adults with bipolar disorder?</p>	
<p>23. What are the <b>adverse effects of short-term and long-term medication exposure</b> between and within antipsychotic classes for adolescents/young adults with bipolar disorder, and how do these adverse effects vary based on patient characteristics?</p>	